The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.

GLP-1 (glucagon-like peptide-1) discovered in the 1980s functions as a hormone derived from the proglucagon sequence and was found to have a transformative impact on the treatment of diabetes and ...

GLP-1 agonist initiators had a significantly higher likelihood of undergoing thyroid ultrasonography at 6 and 12 months, ...

Adults with type 2 diabetes using a GLP-1 drug have a similar risk for thyroid cancer as those using other diabetes drugs, though increased thyroid cancer risk was observed in the first year after GLP ...

HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online January ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart ...

Furthermore, there is a growing trend towards the adoption of technologically advanced solutions, such as digital health platforms and telemedicine, for diabetes management. Leveraging these ...

Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of diseases and adverse health outcomes, such as dementia and stroke, a new analysis published in Nature ...

The geroscience hypothesis focuses on extending the healthy lifespan by targeting aging mechanisms. Recent advances in ...

The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...